These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 2274630)

  • 1. Nefazodone: preclinical pharmacology of a new antidepressant.
    Eison AS; Eison MS; Torrente JR; Wright RN; Yocca FD
    Psychopharmacol Bull; 1990; 26(3):311-5. PubMed ID: 2274630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug.
    Taylor DP; Carter RB; Eison AS; Mullins UL; Smith HL; Torrente JR; Wright RN; Yocca FD
    J Clin Psychiatry; 1995; 56 Suppl 6():3-11. PubMed ID: 7649970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noradrenergic denervation alters serotonin2-mediated behavior but not serotonin2 receptor number in rats: modulatory role of beta adrenergic receptors.
    Eison AS; Yocca FD; Gianutsos G
    J Pharmacol Exp Ther; 1988 Aug; 246(2):571-7. PubMed ID: 2900327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuation of the prolactin-stimulating and hyperthermic effects of nefazodone after subacute treatment.
    Walsh AE; Cowen PJ
    J Clin Psychopharmacol; 1994 Aug; 14(4):268-73. PubMed ID: 7962683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability and safety: essentials in antidepressant pharmacotherapy.
    Lader MH
    J Clin Psychiatry; 1996; 57 Suppl 2():39-44. PubMed ID: 8626362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies.
    Owens MJ; Ieni JR; Knight DL; Winders K; Nemeroff CB
    Life Sci; 1995; 57(24):PL373-80. PubMed ID: 7475971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of McN-5707 as a potential antidepressant.
    Shank RP; Gardocki JF; Schneider CR; Vaught JL; Setler PE; Maryanoff BE; McComsey DF
    J Pharmacol Exp Ther; 1987 Jul; 242(1):74-84. PubMed ID: 3039115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
    Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
    J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of serotonin2 (5-HT2) receptors labeled with [3H]spiroperidol by chronic treatment with the antidepressant amitriptyline.
    Peroutka SJ; Snyder SH
    J Pharmacol Exp Ther; 1980 Dec; 215(3):582-7. PubMed ID: 6255132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of selective 5-hydroxytryptamine-2 and nonselective 5-hydroxytryptamine antagonists on the differential-reinforcement-of-low-rate 72-second schedule.
    Marek GJ; Seiden LS
    J Pharmacol Exp Ther; 1988 Feb; 244(2):650-8. PubMed ID: 2894458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regionally specific neural adaptation of beta adrenergic and 5-hydroxytryptamine2 receptors after antidepressant administration in the forced swim test and after chronic antidepressant drug treatment.
    Paul IA; Duncan GE; Powell KR; Mueller RA; Hong JS; Breese GR
    J Pharmacol Exp Ther; 1988 Sep; 246(3):956-62. PubMed ID: 2843636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minaprine, a new drug with antidepressant properties.
    Bizière K; Worms P; Kan JP; Mandel P; Garattini S; Roncucci R
    Drugs Exp Clin Res; 1985; 11(12):831-40. PubMed ID: 3836113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nefazodone: aspects of efficacy.
    Rickels K; Robinson DS; Schweizer E; Marcus RN; Roberts DL
    J Clin Psychiatry; 1995; 56 Suppl 6():43-6. PubMed ID: 7649973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat.
    Lucki I; Nobler MS; Frazer A
    J Pharmacol Exp Ther; 1984 Jan; 228(1):133-9. PubMed ID: 6694097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of anxiety and agitation symptoms during nefazodone treatment of major depression.
    Fawcett J; Marcus RN; Anton SF; O'Brien K; Schwiderski U
    J Clin Psychiatry; 1995; 56 Suppl 6():37-42. PubMed ID: 7649972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of amitriptyline, nefazodone and paroxetine on performance and brain indices of visual selective attention and working memory.
    van Laar MW; Volkerts ER; Verbaten MN; Trooster S; van Megen HJ; Kenemans JL
    Psychopharmacology (Berl); 2002 Aug; 162(4):351-63. PubMed ID: 12172688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule.
    O'Donnell JM; Marek GJ; Seiden LS
    Neurosci Biobehav Rev; 2005; 29(4-5):785-98. PubMed ID: 15893376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some pharmacological properties of new analogs of MP 3022, the 5-HT1A receptor antagonist.
    Chojnacka-Wójcik E; Kłodzińska A; Tatarczyńska E; Paluchowska MH
    Pol J Pharmacol; 1999; 51(5):405-13. PubMed ID: 10817541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacology of a new serotonergic receptor antagonist, LY281067.
    Cohen ML; Fuller RW; Kurz KD; Parli CJ; Mason NR; Meyers DB; Smallwood JK; Toomey RE
    J Pharmacol Exp Ther; 1988 Jan; 244(1):106-12. PubMed ID: 3335993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel serotonergic mechanisms and clinical experience with nefazodone.
    Fontaine R
    Clin Neuropharmacol; 1993; 16 Suppl 3():S45-50. PubMed ID: 8131154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.